

John A. Todd
NuGEN Technologies, Inc.
Vice President, Marketing
650.590.3654
jtodd@nugeninc.com

Media Contacts:
Carolyn Hawley
Atkins + Associates
858.527.3484
chawley@irpr.com

**Ovation™ System to Be Implemented by Premier San Francisco Research Institution's
Microarray Core Facility, as Standard RNA Amplification and Labeling System**

Facility to utilize Ovation System for Affymetrix GeneChip® Array analysis

San Carlos, California – June 29, 2004 – NuGEN™ Technologies, Inc., a privately held company developing and commercializing the new standard in nucleic acid amplification and labeling systems, today announced that a premier San Francisco research institution will begin using its Ovation™ Biotin System as the standard RNA amplification and labeling system for small samples in its Genomics Core Laboratory.

The facility, the J. David Gladstone Institutes, an independent, nonprofit biomedical research institution affiliated with the University of California, San Francisco (UCSF), will make the Ovation System available to its many users for new studies requiring RNA amplification and labeling.

“The Genomics Core Laboratory needed a way to decrease time-to-result while conserving precious samples. NuGEN's Ovation Biotin System for Affymetrix GeneChip® array analysis provides the sensitivity and accuracy the researchers need while requiring a 1,000-fold smaller sample than the previous protocol. This enables them to conserve their samples, which might be derived from scarce sources, such as biopsies or clinical samples,” said Elizabeth Hutt, vice president of sales and technical service at NuGEN.

The Genomics Core Laboratory at the Gladstone Institutes provides functional genomics solutions for Gladstone, as well as some UCSF labs. The facility prepares, produces, and analyzes DNA microarrays and serves as one of several reference labs at Gladstone and UCSF to test and validate microarray methods for Gladstone and UCSF researchers. Gladstone is comprised of three institutes: the Gladstone Institute of Cardiovascular Disease, the Gladstone Institute of Virology and Immunology, and the Gladstone Institute of Neurological Disease. They are located at the San Francisco General Hospital campus of UCSF. While independent, Gladstone is affiliated with UCSF, and Gladstone investigators hold university appointments.

“Because Ovation Systems offer a one-day method for amplifying and labeling all samples, versus the two- to five-day procedures of the previous protocol, lab researchers say they expect productivity to increase significantly,” said Jan D'Alvise, President and CEO of NuGEN. Core lab adoption of the Ovation RNA Amplification System acknowledges the power of the Ovation Biotin System for Affymetrix GeneChip array applications.”

About NuGEN Technologies Inc.

NuGEN Technologies is focused on the development and commercialization of sensitive, rapid and cost-effective amplification and detection systems for genomic and proteomic research. The company's technologies enable the comprehensive analysis and discovery of biological mechanisms, cellular responses, and disease pathologies. NuGEN's proprietary SPIA™ and Ribo-SPIA™ amplification and labeling technology for DNA and RNA based applications, form the foundation for a wide range of methods and products used by life scientists. The Ovation™ amplification and labeling system, the company's first commercially available product line, has applied these technologies to enhancing the sensitivity, convenience, and accuracy of gene expression analysis. Based in San Carlos, CA, NuGEN has a world-class investor syndicate, several collaborations with leading academic and commercial organizations and a management team with significant experience developing and marketing products for research or clinical diagnostic applications.

NuGEN, Ovation, SPIA and Ribo-SPIA are trademarks or service marks of NuGEN Technologies, Inc.

This press release contains forward-looking statements that are subject to risks and uncertainties, including continued growth in demand by researchers for total RNA analysis, continued use of oligo and cDNA microarrays, acceptance by researchers of the Company's technologies and products, and competition from existing and newly developed products. Accordingly, actual results may differ materially from those anticipated. These forward-looking statements represent the Company's current expectations as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.